All In MedTech

Device Trial Radar · NCT06282809

The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Dec 10, 2024

Primary completion

Mar 2028

Study completion Aug 2028

Sponsor

Lead sponsor
HistoSonics, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Feb 28, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy.

Conditions

  • Pancreas Cancer
  • Adenocarcinoma of the Pancreas
  • Pancreatic Cancer
  • Tumor of Pancreas

Interventions

  • HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsyDevice

    Histotripsy is a non-thermal, mechanical process of focused ultrasound used to mechanically destroy targeted soft tissue.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsyTime frame: 30 days post histotripsy procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.